Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic

Current and future perspective

Matti Aapro, Li Zhang, Sriram Yennu, Thomas W. Leblanc, Lee Schwartzberg

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

Original languageEnglish (US)
Pages (from-to)1067-1084
Number of pages18
JournalFuture Oncology
Volume15
Issue number10
DOIs
StatePublished - Apr 1 2019

Fingerprint

Antiemetics
Nausea
Vomiting
Drug Therapy
Guidelines
Patient Compliance
Pharmacokinetics
netupitant
palonosetron
Physicians
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic : Current and future perspective. / Aapro, Matti; Zhang, Li; Yennu, Sriram; Leblanc, Thomas W.; Schwartzberg, Lee.

In: Future Oncology, Vol. 15, No. 10, 01.04.2019, p. 1067-1084.

Research output: Contribution to journalArticle

@article{b586363366ce4dc0b8a34df59903562b,
title = "Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: Current and future perspective",
abstract = "Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.",
author = "Matti Aapro and Li Zhang and Sriram Yennu and Leblanc, {Thomas W.} and Lee Schwartzberg",
year = "2019",
month = "4",
day = "1",
doi = "10.2217/fon-2018-0872",
language = "English (US)",
volume = "15",
pages = "1067--1084",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic

T2 - Current and future perspective

AU - Aapro, Matti

AU - Zhang, Li

AU - Yennu, Sriram

AU - Leblanc, Thomas W.

AU - Schwartzberg, Lee

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

AB - Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

UR - http://www.scopus.com/inward/record.url?scp=85064227594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064227594&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0872

DO - 10.2217/fon-2018-0872

M3 - Article

VL - 15

SP - 1067

EP - 1084

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 10

ER -